Answers are grounded in this paper and cite their sources.
BACKGROUND: Sacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate (ADC) approved for use in HER2-negative metastatic breast cancer (MBC). This study explores whether Trop-2 expression serves as a biomarker of excellent response versus non-response to sacituzumab govitecan (SG) in HER2-negative MBC. METHODS: Trop-2 expression was determined from patients with HER2-negative MBC categorized as non-responders and excellent responders to SG. Excellent response was defined by a complete or partial response and a progression-free survival (PFS) greater than the median of the cohort. Non-response was defined by progressive disease within 3 months. Trop-2 expression was determined based on percentage of cells staining and a histochemical score (H-score). RESULTS: Of the 15 patients with HER2-negative MBC (8 non-responders/7 excellent responders), the median Trop-2 expression rate was 100 % in both groups (p=0.3). H-score was also similar between the groups, with a median H-score of 270 (range 25-300) in non-responders and 280 (range 120-290) in responders (p=1.0). Lower Trop-2 percent expression was associated with shorter PFS (hazard ratio [HR]: 0.014; 95 % CI, 0-0.52; p=0.018), although Trop-2 expression by H-score was not predictive of PFS (HR: 0.994; 95 % CI, 0.987-1.002; p=0.12). One non-responder had an H-score of 25, which may represent a complete lack of Trop-2 expression. DISCUSSION: In this study, Trop-2 expression did not predict excellent response versus non-response to SG in patients with HER2-negative MBC. Low Trop-2 expression, as determined by percentage staining, was predictive of shorter PFS, although the same association was not observed using the H-score. A complete lack of Trop-2 expression may predict SG ineffective, which requires further investigation.
No takes yet. Share an insight, caveat, or question.
LeVee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: